Loading people...
Eliot Charles is a Venture Partner at SR One, a leading venture capital firm focused on life science investments. He plays a key role in identifying and supporting innovative early-stage companies in biotechnology, pharmaceuticals, and digital health.
Eliot Charles, through his role at SR One, invests in early-stage life science companies. His focus areas include novel therapeutics, diagnostics, medical devices, and digital health platforms that address significant unmet medical needs.
Eliot Charles works as a Venture Partner at SR One. SR One is a prominent venture capital firm dedicated to investing in and building transformative life science companies globally.
Eliot Charles is the Chief Executive Officer of Codify Therapeutics and a Venture Partner at SR One, based in the San Francisco Bay Area. Before assuming his current leadership positions, he served as a Venture Partner at Alta Partners and worked as an Investment Director at Johnson & Johnson Development Corporation. At Codify Therapeutics, he currently directs a preclinical-stage biotechnology enterprise focused on developing novel oncology treatments that specifically exploit alternative RNA splicing mechanisms. In his concurrent investment capacity at SR One Capital Management, Charles leverages decades of corporate venture experience to build, operate, and finance early-stage life sciences and therapeutic startups across the broader healthcare industry. Holding a doctorate degree, his professional focus remains centered on guiding emerging biotechnology ventures through their initial corporate formation, early preclinical research, and subsequent clinical development phases.
Eliot Charles is a distinguished Venture Partner at SR One, a prominent venture capital firm with a rich history of investing in and nurturing transformative life science companies. At SR One, Eliot plays a pivotal role in shaping the future of healthcare by identifying and backing innovative early-stage ventures. His work is critical in sourcing, evaluating, and supporting companies that are developing cutting-edge solutions in biotechnology, pharmaceuticals, and digital health.
SR One has a long-standing reputation for its deep expertise in the life sciences sector, and Eliot Charles embodies this commitment. His investment focus areas typically align with SR One's strategic priorities, which include novel therapeutics, diagnostics, medical devices, and health technology platforms designed to address significant unmet medical needs. He is particularly interested in companies that demonstrate strong scientific foundations, compelling intellectual property, and the potential for significant market impact. Eliot's contributions help to expand SR One's robust portfolio of companies poised to revolutionize patient outcomes.
While specific details of Eliot Charles's career background are not publicly detailed, a Venture Partner in his position typically brings a wealth of experience from various facets of the life science ecosystem. This often includes a strong scientific or medical foundation, potentially coupled with entrepreneurial experience, corporate development roles within pharmaceutical or biotech companies, or prior venture capital expertise. Such a background equips him with the unique insights necessary to assess complex scientific innovations and guide nascent companies through critical development stages. His strategic acumen is vital for portfolio companies navigating the challenging landscape of drug discovery, clinical development, and commercialization.
Eliot Charles is deeply involved in the venture capital process, from initial due diligence to active portfolio management. He collaborates closely with founders and management teams, offering strategic guidance, operational support, and access to SR One's extensive network of industry experts and resources. Although specific notable investments attributed solely to Eliot Charles are not widely publicized, his work directly contributes to the success and growth of SR One's overall portfolio. He is dedicated to fostering companies that not only promise financial returns but also hold the potential to make a profound positive impact on global health. His commitment to identifying and empowering the next generation of life science leaders underscores his significant influence within the venture capital community and the broader healthcare innovation landscape.
